These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 31801292)

  • 1. Teaching an Old Molecule New Tricks: Drug Repositioning for Duchenne Muscular Dystrophy.
    Vitiello L; Tibaudo L; Pegoraro E; Bello L; Canton M
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31801292
    [No Abstract]   [Full Text] [Related]  

  • 2. A Network Medicine Approach for Drug Repurposing in Duchenne Muscular Dystrophy.
    Lombardo SD; Basile MS; Ciurleo R; Bramanti A; Arcidiacono A; Mangano K; Bramanti P; Nicoletti F; Fagone P
    Genes (Basel); 2021 Apr; 12(4):. PubMed ID: 33918694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The golden retriever model of Duchenne muscular dystrophy.
    Kornegay JN
    Skelet Muscle; 2017 May; 7(1):9. PubMed ID: 28526070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing.
    Hanson B; Wood MJA; Roberts TC
    RNA Biol; 2021 Jul; 18(7):1048-1062. PubMed ID: 33472516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The X-linked Becker muscular dystrophy (bmx) mouse models Becker muscular dystrophy via deletion of murine dystrophin exons 45-47.
    Heier CR; McCormack NM; Tully CB; Novak JS; Newell-Stamper BL; Russell AJ; Fiorillo AA
    J Cachexia Sarcopenia Muscle; 2023 Apr; 14(2):940-954. PubMed ID: 36628607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Corticosteroids in Duchenne muscular dystrophy: a reappraisal.
    Wong BL; Christopher C
    J Child Neurol; 2002 Mar; 17(3):183-90. PubMed ID: 12026233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levels of α7 integrin and laminin-α2 are increased following prednisone treatment in the mdx mouse and GRMD dog models of Duchenne muscular dystrophy.
    Wuebbles RD; Sarathy A; Kornegay JN; Burkin DJ
    Dis Model Mech; 2013 Sep; 6(5):1175-84. PubMed ID: 23846963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-dystrophin T cell responses in Duchenne muscular dystrophy: prevalence and a glucocorticoid treatment effect.
    Flanigan KM; Campbell K; Viollet L; Wang W; Gomez AM; Walker CM; Mendell JR
    Hum Gene Ther; 2013 Sep; 24(9):797-806. PubMed ID: 24010700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological advances for treatment in Duchenne muscular dystrophy.
    Guiraud S; Davies KE
    Curr Opin Pharmacol; 2017 Jun; 34():36-48. PubMed ID: 28486179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prednisone reduces muscle degeneration in dystrophin-deficient Caenorhabditis elegans.
    Gaud A; Simon JM; Witzel T; Carre-Pierrat M; Wermuth CG; Ségalat L
    Neuromuscul Disord; 2004 Jun; 14(6):365-70. PubMed ID: 15145337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Genetic Diagnosis and Molecular Therapies for Duchenne Muscular Dystrophy].
    Takeshima Y
    Rinsho Byori; 2015 Oct; 63(10):1194-201. PubMed ID: 26897856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Micro-Dystrophin Gene Therapy Goes Systemic in Duchenne Muscular Dystrophy Patients.
    Duan D
    Hum Gene Ther; 2018 Jul; 29(7):733-736. PubMed ID: 29463117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.
    Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A; Mamchaoui K; Aoki Y; Takeda S; Nagaraju K; Mouly V; Maruyama R; Duddy W; Yokota T
    Mol Ther; 2017 Nov; 25(11):2561-2572. PubMed ID: 28865998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
    Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
    Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials.
    Kornegay JN; Spurney CF; Nghiem PP; Brinkmeyer-Langford CL; Hoffman EP; Nagaraju K
    ILAR J; 2014; 55(1):119-49. PubMed ID: 24936034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutics for Duchenne muscular dystrophy: current approaches and future directions.
    Bogdanovich S; Perkins KJ; Krag TO; Khurana TS
    J Mol Med (Berl); 2004 Feb; 82(2):102-15. PubMed ID: 14673527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Causes of clinical variability in Duchenne and Becker muscular dystrophies and implications for exon skipping therapies.
    Hoffman EP
    Acta Myol; 2020 Dec; 39(4):179-186. PubMed ID: 33458572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologic and genetic therapy for childhood muscular dystrophies.
    Escolar DM; Scacheri CG
    Curr Neurol Neurosci Rep; 2001 Mar; 1(2):168-74. PubMed ID: 11898513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review on mechanistic insights into structure and function of dystrophin protein in pathophysiology and therapeutic targeting of Duchenne muscular dystrophy.
    Elasbali AM; Al-Soud WA; Anwar S; Alhassan HH; Adnan M; Hassan MI
    Int J Biol Macromol; 2024 Apr; 264(Pt 1):130544. PubMed ID: 38428778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of Duchenne muscular dystrophy with gentamicin].
    Matsuo M; Takeshima Y; Yagi M; Ishibashi K; Wada H
    No To Hattatsu; 2004 Mar; 36(2):125-9. PubMed ID: 15031986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.